Wegovy maker Novo Nordisk’s shares plunge as it cuts sales forecast
by Reuters from World news | The Guardian on (#6YZ3K)
Pharma group names Maziar Mike Doustdar as new CEO as it seeks to convince investors it is not lagging behind rival Eli Lily
The obesity drugmaker Novo Nordisk has cut its full-year sales and operating profit forecasts for the second time this year, sending its shares down by more than a fifth on Tuesday.
The maker of the weight-loss drug Wegovy is struggling to convince investors it can remain competitive in the obesity drug boom against US rival Eli Lilly.
Continue reading...